Thermo Fisher Scientific Inc. (NYSE:TMO)
March 21st, 2019
Amidst rising markets Thermo Fisher Scientific Inc. closed Thursday up 2.04%, a $5.42 increase to close on $271.05. Furthermore it hit a new 52 week high of $271.70.
Thermo Fisher Scientific Inc. is listed on the S&P 500 index, and was one of 436 stocks that increased today. Weighted by market cap, TMO represents about 0.42% of the S&P 500.
Analysis results from 16 analysts suggest that Thermo Fisher Scientific Inc. might increase somewhat (0.90%), while Finbox has calculated (with low uncertainty) a fair value price of $221.09.
The market sectors were mixed Thursday with a majority of the sectors trending up. Information Technology saw the biggest increase of the day (2.47%), while Financials saw the biggest drop (-0.30%). Information Technology has seen the biggest year-to-date gain at 18.16%.
Real Estate saw the biggest turnaround from its 5-day performance of -0.72%, as it went up 1.79%. Financials saw a turn around from its 5-day performance of -0.81% trading down -0.30%.
- Information Technology went up with a 2.47% change.
- Real Estate went up with a 1.79% change.
- Consumer Discretionary went up with a 1.32% change.
- Consumer Staples went up with a 1.19% change.
- Utilities went up with a 1.05% change.
- Materials went up with a 1.04% change.
- Industrials went up with a 0.95% change.
- Communication Services went up with a 0.89% change.
- Energy went up with a 0.69% change.
- Healthcare went up with a 0.35% change.
- Financials went down with a -0.30% change.
Thermo Fisher Scientific Inc. Info
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment offers instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. Its Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel products. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Its Laboratory Products and Services segment offers laboratory refrigerators and freezers, ultralow-temperature freezers and cryopreservation storage tanks, temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis and laboratory equipment; laboratory plastics; laboratory chemicals; research and safety market channel; and pharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.